US Stock IR Daily – April 08, 2026 (3 reports)

• Exxon Mobil Corporation filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC).
• The report is dated April 8, 2026.
• The filing was made pursuant to Item 7.01, Regulation FD Disclosure.
• The report included Exhibit 99.1, titled “Exxon Mobil Corporation 1Q26 Earnings Considerations.”
• It also included Exhibit 99.2, titled “Update on impact of Middle East conflict on ExxonMobil activities.”

ExxonMobil has disclosed significant information with the SEC under Regulation FD. This action suggests that the market now has access to details regarding potential factors affecting its first-quarter 2026 earnings and the specific impact of the Middle East conflict on its operations. Investors may consider these disclosures key in evaluating the company’s prospective outlook.

• Regeneron Pharmaceuticals, Inc. anticipates an acquired in-process research and development (IPR&D) charge of approximately $102 million on a pre-tax basis for the first quarter of 2026.
• This IPR&D charge primarily stems from premiums on equity securities purchased, as well as development milestone and upfront payments associated with collaboration and licensing agreements.
• The charge is expected to negatively impact both GAAP and non-GAAP net income per diluted share for Q1 2026 by approximately $0.81.
• Regeneron does not forecast such acquired IPR&D charges due to the uncertainty surrounding their future occurrence, magnitude, and timing in any given period.
• The company’s first quarter 2026 results are preliminary, unaudited, and subject to finalization procedures, meaning actual results could differ from these estimates.

For a biotechnology company like Regeneron, acquired IPR&D charges are common and typically reflect investments in future growth, such as new collaborations or asset acquisitions. While these charges are expected to impact earnings per share for the quarter, they are often non-recurring and relate to the company’s long-term research and development strategy. Investors may view such charges in the context of a company’s pipeline development and strategic expansion, with the final audited results providing a complete picture.

• U.S. Bancorp implemented certain changes and reclassifications to the presentation of its Consolidated Statement of Income and Consolidated Balance Sheet, effective January 1, 2026.
• These changes are intended to align financial reporting with the management of the Company’s businesses.
• The reclassifications have no impact on the Company’s historical total net revenues, provision for credit losses, operating expenses, and net income on the Consolidated Statement of Income.
• Furthermore, there is no impact on total loans or total assets on the Consolidated Balance Sheet, nor on the Company’s return on average assets, return on average common equity, and diluted earnings per common share.
• One primary change is the renaming of “Corporate payment products revenue” to “Corporate payment and treasury management revenue,” which now includes revenue from treasury management services (previously in “Service charges”) and stored-value card revenue (previously in “Card revenue”).

This announcement indicates U.S. Bancorp is enhancing the clarity and alignment of its financial reporting with its internal business management. As the company explicitly states no impact on core financial metrics such as net revenues, net income, total assets, or key profitability ratios, these reclassifications primarily reflect a presentation adjustment rather than a change in underlying business performance or financial health. Investors may view this as an effort to provide more transparent and relevant financial information.